Vir Biotechnology, Inc.
Vir Biotechnology, Inc.
Explore linked clinical trials.9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-10-07 | NCT05997615 | |
| To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | Locally Advanced or Metastatic HER2-Expressing Cancers | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT05356741 | |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | Chronic Disease, Digestive System Diseases, Disease Attributes, Hepatitis D, Chronic, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 3 | 2026-07-13 | NCT07128550 | |
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | Chronic Disease, Digestive System Diseases, Disease Attributes, Hepatitis D, Chronic, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 2 | 2026-06-26 | NCT05461170 | |
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | EGFR; EGFR Positive Solid Tumors; Solid Tumor Malignancies | Recruiting | Phase 1 | 2026-04-13 | NCT06960395 | |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Chronic Disease, Digestive System Diseases, Disease Attributes, Hepatitis D, Chronic, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 3 | 2026-04-08 | NCT06903338 | |
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Chronic Disease, Digestive System Diseases, Disease Attributes, Hepatitis D, Chronic, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 2 | 2026-01-16 | NCT07142811 | |
| Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 2 | 2025-09-05 | NCT05970289 | |
| Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) | For Treatment of Chronic Hepatitis B Virus Infection | Active, not recruiting | Phase 2 | 2024-12-30 | NCT06491563 |